This special issue aims to explore the latest advancements in the treatment of urological cancers, focusing on recent progress in drug development, innovative clinical trials, and novel therapeutic strategies. Contributions should highlight new findings in targeted therapies, immunotherapy, and combination treatments that address common urological malignancies such as prostate, bladder, and renal cancers. Submissions can include original research, review articles, and case studies emphasizing translational research that bridges the gap between laboratory science and clinical application. Topics on emerging biomarkers, drug delivery systems, and precision medicine approaches are highly encouraged, along with studies that assess patient outcomes and quality of life.